Business
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid
About this update from Enlivex Ltd.
[{"type":"text","content":"Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancersReceived Israeli Ministry of Health approval to initiate a Phase I/II trial evaluating Allocetra™ alone and in combination with a PD1 checkpoint inhibitor in patients with advanced solid tumors.Announced preclinical data in ovarian cancer (in collaboration with Yale Cancer Center) and mesothelioma showing substantial, statistically significant survival benefits when Allocetra™ is combined with PD1 or CTLA4 checkpoint inhibition, respectivelyAppointed new Vice Chairman of the Board, Dr. Roger J. Pomerantz, who previously served as Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, Venture Partner at Flagship Pioneering, and President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today filed with the SEC its financial results and related management’s discussion for the second quarter ended June 30, 2022. “Our recent progress was highlighted by key advancements in our oncology program, including the initiation of our first oncology clinical trial and important preclinical data announcements,” said Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex. “Studies in murine models of ovarian cancer, in collaboration with the Yale Cancer Center, and mesothelioma, showed substantial, synergistic survival benefits when checkpoint inhibitors were combined with Allocetra™, showcasing its broadly applicable immunotherapeutic effects. Together with prior data, we believe that these findings support our ongoing chemotherapy combination trial and provide a strong scientific rationale for an upcoming trial designed to evaluate Allocetra™ alone and in combination with a PD1 checkpoint inhibitor in patients with advanced solid tumors.” Dr. Hershkovitz continued, “Alongside our progress in oncology, we began a regulatory effort to incorporate Allocetra’s™ frozen formulation into our Phase II sepsis trial and to expand the study’s target patient population to include various sources of sepsis in order to po...